ICON Acquires MediMedia Pharma Solutions
ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has agreed, subject to certain customary closing conditions, to acquire MediMedia Pharma Solutions for a cash consideration of $120 million.
ICON
announced its intention to acquire MediMedia Pharma Solutions for $120 million. MediMedia Pharma Solutions provides strategic payer-validated market access solutions, and medical and scientific communication agencies working with medical affairs, commercial and brand development teams within life science companies. The acquisition strengthens ICON’s expertise in scientific communications and market access. Read the full release
here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMGSeptember 15th 2025
Q&A: Strategies for Successful Global Clinical Trial DeliverySeptember 12th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
